Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 8 Jun 2022 |
| Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting | 6 Jun 2022 |
| Major Shareholder Announcement | 1 Jun 2022 |
| Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | 26 May 2022 |
| Genmab A/S has published its Articles of Association | 18 May 2022 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 17 May 2022 |